newsfilter
← Latest News
GlobeNewswire·

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease (PD) on track to report interim safety and immunogenicity dataPrescreening